Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 7Cyclophosphamide 6Doxorubicin 5pembrolizumab 3Trastuzumab 3Taxes 3Specimen Handling 3Carboplatin 3pertuzumab 2eribulin 2Radiotherapy 2Epirubicin 2Docetaxel 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1ruxolitinib 1pegfilgrastim 1onvansertib 1olaparib 1neratinib 1durvalumab 1cobimetinib 1atezolizumab 1X-Rays 1Therapeutics 1Tamoxifen 1Surgical Procedures, Operative 1Radiation 1Peripheral Blood Stem Cell Transplantation 1Panitumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inflammatory Breast Neoplasms × onvansertib × 1 year × Clear all
NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡